Acura Pharmaceuticals, Inc.  

(Public, OTCMKTS:ACUR)   Watch this stock  
Find more results for NASDAQ:ACUR
-0.010 (-1.82%)
Jun 23 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.51 - 0.55
52 week 0.40 - 2.18
Open 0.55
Vol / Avg. 6,233.00/13,620.00
Mkt cap 6.42M
P/E     -
Div/yield     -
EPS -0.30
Shares 11.88M
Beta 2.09
Inst. own 35%
Apr 3, 2017
Q4 2016 Acura Pharmaceuticals Inc Earnings Call

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin 14.91% -165.50%
Operating margin 21.42% -146.89%
EBITD margin - -138.58%
Return on average assets 19.04% -58.71%
Return on average equity 112.19% -162.68%
Employees 15 -
CDP Score - -


616 N North Ct Ste 120
PALATINE, IL 60067-8121
United States - Map
+1-847-7057709 (Phone)
+1-847-7055399 (Fax)

Website links


Acura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company's Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company's Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company's Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine.

Officers and directors

Robert B. Jones President, Chief Executive Officer, Director
Age: 56
Peter A. Clemens Chief Financial Officer, Senior Vice President, Secretary
Age: 62
Robert A. Seiser CPA Vice President, Corporate Controller and Treasurer
Age: 51
J. Bradley Rivet Vice President - Marketing
Age: 61
Albert W. Brzeczko Ph.D. Vice President -Technical Affairs
Age: 58
James F. Emigh Vice President - Corporate Development
Age: 59
George K. Ross Independent Director
Age: 73
William G. Skelly Independent Director
Age: 64
Immanuel Thangaraj Independent Director
Age: 44
Bruce F. Wesson Independent Director
Age: 73